GLP-3RTA is the research-identity listing for retatrutide, an investigational triple hormone receptor agonist acting on GIP, GLP-1, and glucagon receptors. Retatrutide remains in active Phase 3 trials and is not FDA-approved for any use. Sold strictly for laboratory research use.
HPLC certified
Independent analysis
Highest standard
Full traceability
Each order ships as retatrutide research peptide in your choice of 10, 20, 30, or 60 mg vials, manufactured for laboratory use only.
| Compound | Retatrutide |
|---|---|
| Development Code | LY3437943 |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C221H342N46O68 |
| Molecular Weight | 4,731.3 g/mol |
| PubChem CID | Not independently confirmed as of this writing |
| Physical Form | Lyophilized powder |
| Purity | Not independently verified for this listing — no batch-specific COA is currently published |
| Identity | Identity-testing method not currently disclosed on this page |
| Available Sizes | 10 mg / 20 mg / 30 mg / 60 mg |
| Intended Use | Laboratory research only (RUO) |
When your order arrives, match the lot number printed on the vial to the lot number on the COA before beginning any work. Until a GLP-3RTA-specific COA is published, treat any purity figure shown elsewhere on this listing as a supplier claim, not an independently verified result.
Retatrutide reached −24.2% mean weight change at 48 weeks in phase 2. What the NEJM and Lancet trials show, what's unproven, and how RUO batches are verified.
HCG and LH bind the exact same receptor — yet research shows they send measurably different signals once they do. Here's what's actually established about HCG's structure, mechanism, and the FDA's position on HCG weight-loss claims.
No peer-reviewed human study of IGF-1 LR3 exists — a 2026 literature review placed it in its lowest evidence tier. Here's what the cell and animal research actually shows, and where it stops.
